Study With Mitomycin c/5-FU/FA in Pretreated Gastrointestinal Cancer Patients With Metastases (>= Second-line Treatment)
Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The aim of this study was to define the maximum tolerated dose (MTD) of bolus mitomycin C
(MMC) in combination with 24 h-continuous infusion of 5-fluorouracil (FU) plus folinic acid,
and to assess the toxicity and activity in patients with previously treated colorectal and
gastric cancer. Escalating doses of MMC starting from 6 mg m(-2) in 2 mg m(-2)-steps to a
maximum of 10 mg m(-2) were applied on days 1 and 22, given to fixed doses of 5-FU (2.600 mg
m(-2)) as 24 h infusion and folinic acid 500 mg m(-2) prior to 5-FU weekly for 6 weeks